Back to results

Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis (SariPRO)

Primary Purpose

Rheumatoid Arthritis

Status

Completed

Phase

Phase 4

Locations

France

Study Type

Interventional

Intervention

SARILUMAB

Azathioprine

Chloroquine

Hydroxychloroquine

Leflunomide

Methotrexate

Sulfasalazine

About this trial

This is an interventional treatment trial for Rheumatoid Arthritis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria :

Participants with moderately to severely active RA to European League against Rheumatology (EULAR)/American College of Rheumatology (ACR) Criteria.
Participants with moderate to severe disease activity defined as a DAS28-ESR greater than (>) 3.2 at Screening.
Participants with inadequate response within at least the last 3 months or intolerance to current csDMARD or to at least one anti-TNF therapy (as defined by the investigator).
Oral corticosteroids (less than or equal to [<=] 15 mg/day prednisone or equivalent) and nonsteroidal anti-inflammatory drugs or cyclooxygenase-2 (up to the maximum recommended dose) were allowed if taken at a stable dose for at least 4 weeks prior to Baseline.
Permitted csDMARDs were allowed if taken at a stable dose for at least 4 weeks prior to Baseline.
Participants abled and given written informed consent and complied with the requirements of the study protocol.

Exclusion criteria:

Less than (<) 18 years of age.
Participant unable to understand and write adequately to complete the study participant related outcome assessments.
Exposure to sarilumab at any time prior to Baseline visit.
Use of intra-articular or parenteral corticosteroids within 4 weeks prior to Baseline.
Treatment with any investigational agent within the 4 weeks of Screening.
Last RA treatment prior to inclusion with any anti-Janus kinase (JAK) or biologic DMARD other than anti-TNF.
Participants treated with anti-TNF (i.e. adalimumab, infliximab, certolizumab, golimumab, etanercept) before the screening period, which are maintained within the 4 weeks before the inclusion (i.e. the first injection of sarilumab).
Rheumatic autoimmune disease other than RA or prior history or current inflammatory joint disease other than RA.
Evidence of active malignant disease, malignancies diagnosed within the previous 10 years (except basal and squamous cell carcinoma of the skin or carcinoma in situ of the cervix uteri previously excised and cured).
Participant who was institutionalized due to regulatory or legal order or participant who was mentally disabled or educationally disadvantaged.
Pregnant or breastfeeding woman.
Women of childbearing potential not protected by highly-effective contraceptive method(s) of birth control (as defined in the informed consent form and/or in a local protocol addendum/amendment) over the study period and for at least 3 months following the last dose of sarilumab, and/or who are unwilling or unable to be tested for pregnancy.
History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies (or to any of the excipients associated to sarilumab).
Immunization with a live/attenuated vaccine within 4 weeks prior to Baseline.
Stage III or IV cardiac failure according to the New York Heart Association classification.
History of previous gastrointestinal perforation or diverticulitis.
Known active current/ recurrent infections (including but not limited to active tuberculosis [TB] or history of incompletely treated TB and atypical mycobacterial disease, hepatitis B and C, and herpes zoster). NOTE: in case of latent TB infection the participant might be included if a subsequent appropriate anti TB treatment is initiated since at least 3 weeks.
Positive hepatitis B surface antigen, and/or positive total hepatitis B core antibody, and/or positive hepatitis C antibody at the Screening visit.
Evidence of serious uncontrolled concomitant disease, including severe uncontrolled hypercholesterolemia or hypertriglyceridemia.
Participants with any of the following laboratory abnormalities at the Screening or Baseline visit:
- Hemoglobin <8.5 grams per deciliter.
- White blood cells <3000/cubic millimeter (mm^3).
- Absolute neutrophil count <2000/mm^3
- Absolute lymphocyte count <500/mm^3
- Platelet count <150 000 cells/mm^3
- Creatinine clearance <30 milliliter per minute.
- Aspartate aminotransaminase or Alanine aminotransaminase >1.5 x upper limit of normal (ULN).
- Bilirubin (total) >ULN, unless Gilbert's disease has been determined by genetic testing and has been documented
- Total fasting cholesterol >3.50 gram per liter (g/L) [9.1 millimoles per liter {mmol/L}]) or triglycerides >5.00 g/L [5.6 mmol/L]).

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Sarilumab

Arm Description

Sarilumab 200 milligram (mg) subcutaneous (SC) injection every 2 weeks (q2w) from Day 1 of Week 0 up to Week 24 as monotherapy and/or in combination with methotrexate (MTX) or other csDMARD during the randomized 6-month (24 weeks) core treatment period. Participants completing 24 weeks period entered in a long-term extension treatment period and received sarilumab 200 mg q2w from Week 25 until the commercial availability of sarilumab in the country or maximum of up to Week 39.7.

Outcomes

Primary Outcome Measures

Change From Baseline in Rheumatoid Arthritis Impact of Disease Total Score at Week 24

RAID was a participant reported outcome measure used to evaluate the impact of RA on participant's quality of life which comprised 7 domains: • pain, • function, • fatigue, • physical and psychological well-being, • sleep disturbance, and • coping. Each domain was a single question scored on a 0 to 10 continuous NRS. The values for each of these domains were weighed by participant assessment of relative importance and combined in a single value. Total RAID score range was 0 (not affected, very good) to 10 (most affected), where higher value indicated worse status.

Secondary Outcome Measures

Rheumatoid Arthritis Impact of Disease Total Score at Baseline, Weeks 4, 12 and 24

RAID was a participant reported outcome measure used to evaluate the impact of RA on participant's quality of life which comprised 7 domains: • pain, • function, • fatigue, • physical and psychological well-being, • sleep disturbances, and • coping. Each domain was a single question scored on a 0 to 10 continuous NRS. The values for each of these domains were weighed by participant assessment of relative importance and combined in a single value. Total RAID score range was 0 (not affected, very good) to 10 (most affected), where higher value indicated worse status.

Change From Baseline in Rheumatoid Arthritis Impact of Disease Total Score at Weeks 4 and 12

RAID was a participant reported outcome measure used to evaluate the impact of RA on participant's quality of life which comprised 7 domains: • pain, • function, • fatigue, • physical and psychological wellbeing, • sleep disturbance, and • coping. Each domain was a single question scored on a 0 to 10 continuous NRS. The values for each of these domains were weighed by participant assessment of relative importance and combined in a single value. Total RAID score range was 0 (not affected, very good) to 10 (most affected), where higher value indicated worse status.

Hospital Anxiety and Depression Scale (HADS): Anxiety (HADS-A) and Depression (HADS-D) Subscale Scores at Baseline, Weeks 4, 12, and 24

HADS questionnaire measures the presence and severity of anxiety and depression in both hospital and community settings. The questionnaire comprised of 14 items divided into 2 subscales: 7 items for anxiety subscale (HADS-A) and 7 items for depression subscale (HADS-D). Each item was scored on a 0 to 3 rating scale. The anxiety and depression subscales each ranged from 0 to 21 (0-7: normal, 8-10: borderline abnormal and 11-21: abnormal), where higher scores indicated greater severity of anxiety/depression. The subscales were independent for each result of depression and anxiety.

Change From Baseline in Hospital Anxiety and Depression Scale: Anxiety (HADS-A) and Depression (HADS-D) Subscale Scores at Weeks 4, 12 and 24

Multidimensional Assessment of Thymic States (MAThyS) Scale Total Score at Baseline, Weeks 4, 12 and 24

MAThyS was a multi-dimensional self-administered questionnaire comprised of five dimensions (emotional reactivity, cognition speed, psychomotor function, motivation and sensory perception) divided into 20 items relating to individual states as perceived by participants for the preceding week (at each specified Week). Each item was measured on a visual analog scale (VAS; in centimeters [cm]) ranged from 0 (inhibition of the state evaluated by the item) to 10 (excitation for the evaluated state). Total MAThyS score was sum of the 20 items and that might vary from score range 0 to 200 with lower scores indicated general inhibition and higher scores indicated general excitation.

Change From Baseline in Multidimensional Assessment of Thymic States Scale Total Score at Weeks 4, 12 and 24

MAThyS was a multi-dimensional self-administered questionnaire comprised of five dimensions (emotional reactivity, cognition speed, psychomotor function, motivation and sensory perception) divided into 20 items relating to individual states as perceived by participants for the preceding week (at each specified Week). Each item was measured on a VAS (in cm) ranging from 0 (inhibition of the state evaluated by the item) to 10 (excitation for the evaluated state). Total MAThyS score was sum of the 20 items and that might vary from score range 0 to 200 with lower scores indicated general inhibition and higher scores indicated general excitation.

Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Total Scores at Baseline, Weeks 4, 12 and 24

FACIT-F was a 13-item questionnaire that assess fatigue in participants under chronic illness therapy. Participants scored each item on a 5-point Likert scale ranged from 0 to 4 (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). The scores of each item were reversed during score calculations, so that higher score values indicated more favorable conditions. Total score was the sum of score from each item and resulted in a score range from 0 to 52, with higher score indicated better participant health status (lower level of fatigue).

Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Total Scores at Weeks 4, 12 and 24

Stanford Health Assessment Questionnaire Disability Index (HAQ-DI) Total Score at Baseline, Weeks 4, 12 and 24

HAQ-DI was a participant-oriented questionnaire developed specifically to assess the extent of a RA participant's functional ability. It consisted of at least 2 or 3 questions per category, participant reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week (at each specified visit) rated on a 4-point scale where 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do. Overall score was computed as the sum of category scores and divided by the number of categories answered, and ranged from 0 to 3, where 0 = no disability and 3 = completely disabled, higher score indicated more disability.

Change From Baseline in Stanford Health Assessment Questionnaire Disability Index Total Score at Weeks 4, 12 and 24

Duration of Morning Stiffness at Baseline, Weeks 4, 12, and 24

Duration of morning stiffness was defined as the time elapsed (in minutes) between the time of usual awakening (even if not in the morning) and the time the participant was able to resume normal activities without stiffness. At each specified time point, duration of morning stiffness was reported by the participant during the visit.

Change From Baseline in Duration of Morning Stiffness at Weeks 4, 12, and 24

International Physical Activity Questionnaire (IPAQ) Total Score at Baseline, Weeks 4, 12 and 24

IPAQ was a 27-item self-reported questionnaire designed to measure physical activity of participant. The score was reported in metabolic equivalent (MET)-minutes per week. MET minutes represented the amount of energy expended to carry out physical activity. For IPAQ total score, the minimum value is zero and there is no maximum. Higher scores mean better levels of physical activity.

Change From Baseline in International Physical Activity Questionnaire Total Score at Weeks 4, 12 and 24

IPAQ was a 27-item self-reported questionnaire designed to measure physical activity of participant. The score was reported in MET minutes per week. MET minutes represented the amount of energy expended to carry out physical activity. For IPAQ total score, the minimum value is zero and there is no maximum. Higher scores mean better levels of physical activity.

Patient Global Assessment (PtGA) of Disease Activity Score by Visual Analog Scale (VAS) at Baseline, Weeks 4, 12 and 24

PtGA of disease activity was measured using a 100 millimeters (mm) horizontal VAS ranged from 0=no pain to 100=maximum pain imaginable, where higher score indicated more disease activity.

Change From Baseline in Patient Global Assessment of Disease Activity Score by Visual Analog Scale at Weeks 4, 12, and 24

PtGA of disease activity was measured using a 100 mm horizontal VAS ranged from 0=no pain to 100=maximum pain imaginable, where higher score indicated more disease activity.

Erythrocyte Sedimentation Rate (ESR) at Baseline, Weeks 4, 12, and 24

ESR was a laboratory test to provide non-specific measure of inflammation in the body. The test assessed the rate at which red blood cells fell in a test tube and was measured in millimeter per hour (mm/h).

Change From Baseline in Erythrocyte Sedimentation Rate at Weeks 4, 12, and 24

ESR was a laboratory test to provide non-specific measure of inflammation in the body. The test assessed the rate at which red blood cells fell in a test tube and was measured in mm/h.

Disease Activity Score-28 for Rheumatoid Arthritis With Erythrocyte Sedimentation Rate (DAS28-ESR) at Baseline, Weeks 4, 12, and 24

DAS28-ESR was a composite score that included 4 variables: tender joint count (TJC) (based on 28 joints); swollen joint count (SJC) (based on 28 joints); participant's global assessment of health activity using 100 mm VAS: range 0 (no pain) to 100 (maximum pain imaginable); marker of inflammation assessed by ESR in mm/h. DAS28-ESR total score ranged from 0-10, higher score indicated more disease activity. The DAS28-ESR score provided a number indicating the current disease activity of the RA. A DAS28-ESR score above 5.1 indicated high disease activity, DAS28-ESR score less than or equal to (<=) 3.2 indicated low disease activity (LDA), greater than (>) 3.2 to <=5.1 implied moderate disease activity and DAS28-ESR score below 2.6 indicated disease remission.

Change From Baseline in Disease Activity Score-28 for Rheumatoid Arthritis With Erythrocyte Sedimentation Rate at Weeks 4, 12, and 24

DAS28-ESR was a composite score that included 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); participant's global assessment of health activity using 100 mm VAS: range 0 (no pain) to 100 (maximum pain imaginable); marker of inflammation assessed by ESR in mm/h. DAS28-ESR total score ranged from 0-10, higher score indicated more disease activity. The DAS28-ESR score provided a number indicating the current disease activity of the RA. A DAS28-ESR score above 5.1 indicated high disease activity, DAS28-ESR score <= 3.2 indicated LDA, > 3.2 to <=5.1 implied moderate disease activity and DAS28-ESR score below 2.6 indicated disease remission.

Clinical Disease Activity Index (CDAI) Total Score at Baseline, Weeks 4, 12, and 24

CDAI was a composite index constructed to measure clinical remission in RA that does not include a laboratory test, and is a numerical summation of 4 components: SJC (28 joints), TJC (28 joints), participant's global disease activity (in cm), and physician's global assessment of disease (in cm). CDAI total score ranges from 0 to 76 with a lower score indicating less disease activity. A CDAI score of <=2.8 represents clinical remission and a score of <=10.0 represents LDA.

Change From Baseline in Clinical Disease Activity Index Total Score at Weeks 4, 12, and 24

Number of Swollen Joints at Baseline, Weeks 4, 12, and 24

Number of joints with swelling are reported. Joints which were assessed included 28 joints (which included shoulders, elbows, wrists, knees and 2 joints in each finger and thumb).

Change From Baseline in Number of Swelling Joints at Weeks 4, 12, and 24

Number of joints with swelling are reported. Joints which were assessed included 28 joints (which included shoulders, elbows, wrists, knees and 2 joints in each finger and thumb).

Number of Tender Joints at Baseline, Weeks 4, 12, and 24

Number of joints with tenderness are reported. Joints which were assessed included 28 joints (which included shoulders, elbows, wrists, knees and 2 joints in each finger and thumb).

Change From Baseline in Number of Tender Joints at Weeks 4, 12, and 24

Number of joints with tenderness are reported. Joints which were assessed included 28 joints (which included shoulders, elbows, wrists, knees and 2 joints in each finger and thumb).

Number of Participants Achieving Low Disease Activity (DAS28 ESR Score <=3.2) and Remission (DAS28 ESR Score <2.6) at Weeks 12, and 24

DAS28-ESR was a composite score that included 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); participant's global assessment of health activity using 100 mm VAS: range 0 (no pain) to 100 (maximum pain imaginable) marker of inflammation assessed by ESR in mm/h. DAS28-ESR total score ranged from 0-10, higher score indicated more disease activity. The DAS28-ESR score provided a number indicating the current disease activity of the RA. A DAS28-ESR score above 5.1 indicated high disease activity, DAS28-ESR score <= 3.2 indicated LDA, > 3.2 to <=5.1 implied moderate disease activity and DAS28-ESR score below 2.6 indicated disease remission.

Number of Participants Achieving Clinical Disease Activity Index: Low Disease Activity (CDAI Score <=10.0) and Remission (CDAI Score <=2.8) Weeks 12, and 24

CDAI was a composite index constructed to measure clinical remission in RA that does not included a laboratory test, and is a numerical summation of 4 components: SJC (28 joints), TJC (28 joints), participant's global disease activity (in cm), and physician's global assessment (in cm). Total score ranged from 0 to 76 with a lower score indicated less disease activity. A CDAI score of <=2.8 represents clinical remission and a score of <=10.0 represents LDA.

Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had a causal relationship with the study treatment. SAE: Any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs were defined as AEs that occurred in the time from the first injection of study drug up to 39.7 weeks.

Full Information

NCT ID

NCT03449758

First Posted

February 8, 2018

Last Updated

March 30, 2022

Sponsor

Sanofi

Collaborators

Regeneron Pharmaceuticals

1. Study Identification

Unique Protocol Identification Number

NCT03449758

Brief Title

Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis

Acronym

SariPRO

Official Title

Effect of Sarilumab on Patient-reported Outcomes in Patients With Moderately to Severely Active Rheumatoid Arthritis and With Inadequate Response or Intolerance to Current Conventional Synthetic DMARDs or Tumor Necrosis Factor Inhibitors

Study Type

Interventional

2. Study Status

Record Verification Date

March 2022

Overall Recruitment Status

Completed

Study Start Date

March 5, 2018 (Actual)

Primary Completion Date

July 31, 2019 (Actual)

Study Completion Date

July 31, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Sanofi

Collaborators

Regeneron Pharmaceuticals

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Studies a U.S. FDA-regulated Device Product

Product Manufactured in and Exported from the U.S.

Data Monitoring Committee

5. Study Description

Brief Summary

Primary Objective: To assess the effect of sarilumab in combination with conventional synthetic Disease-Modifying Anti-Rheumatic Drug (csDMARD) and/or monotherapy on participant-reported impact of disease, using the rheumatoid arthritis impact of disease (RAID) questionnaire, in participants with moderately to severely active rheumatoid arthritis (RA) and inadequate response or intolerance to current csDMARD or tumor necrosis factor (TNF) inhibitors. Secondary Objectives: To assess the change of the RAID score from baseline (to Week 4, Week 12, and Week 24) in participants with moderately to severely active RA and inadequate response or intolerance to current csDMARD or TNF inhibitors, treated with sarilumab in combination with csDMARD and/or monotherapy. To assess the effect of sarilumab in combination with csDMARD and/or monotherapy on other participant-reported outcomes (global assessment of disease activity, disability, morning stiffness, fatigue, anxiety/depression, mood disorders, and physical activities) in participants with moderately to severely active RA and inadequate response or intolerance to current csDMARD or TNF inhibitors. To assess the efficacy of sarilumab in combination with csDMARD and/or monotherapy using disease activity score-28 for RA with erythrocyte sedimentation rate (DAS28-ESR) and clinical disease activity index in participants with moderately to severely active RA and inadequate response or intolerance to current csDMARD or TNF inhibitors. To assess the safety of sarilumab in combination with csDMARD and/or monotherapy in participants with moderately to severely active RA and inadequate response or intolerance to current csDMARD or TNF inhibitors.

Detailed Description

The study duration per participant was approximately 32 weeks, with up to 4-week screening, 24 weeks treatment period, and 2-4 weeks post-treatment observations.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Rheumatoid Arthritis

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 4

Interventional Study Model

Single Group Assignment

Masking

None (Open Label)

Allocation

N/A

Enrollment

84 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Sarilumab

Arm Type

Experimental

Arm Description

Intervention Type

Drug

Intervention Name(s)

SARILUMAB

Other Intervention Name(s)

SAR153191 (REGN88), Kevzara®

Intervention Description

Pharmaceutical form:Solution for injection in pre-filled syringe Route of administration: Subcutaneous

Intervention Type

Drug

Intervention Name(s)

Azathioprine

Intervention Description

Pharmaceutical form:Tablet Route of administration: Oral

Intervention Type

Drug

Intervention Name(s)

Chloroquine

Intervention Description

Pharmaceutical form:Tablet Route of administration: Oral

Intervention Type

Drug

Intervention Name(s)

Hydroxychloroquine

Intervention Description

Pharmaceutical form:Tablet Route of administration: Oral

Intervention Type

Drug

Intervention Name(s)

Leflunomide

Intervention Description

Pharmaceutical form:Tablet Route of administration: Oral

Intervention Type

Drug

Intervention Name(s)

Methotrexate

Intervention Description

Pharmaceutical form:Solution for injection Route of administration: Subcutaneous / Intramuscular

Intervention Type

Drug

Intervention Name(s)

Sulfasalazine

Intervention Description

Pharmaceutical form:Tablet Route of administration: Oral

Primary Outcome Measure Information:

Title

Change From Baseline in Rheumatoid Arthritis Impact of Disease Total Score at Week 24

Description

Time Frame

Baseline, Week 24

Secondary Outcome Measure Information:

Title

Rheumatoid Arthritis Impact of Disease Total Score at Baseline, Weeks 4, 12 and 24

Description

RAID was a participant reported outcome measure used to evaluate the impact of RA on participant's quality of life which comprised 7 domains: • pain, • function, • fatigue, • physical and psychological well-being, • sleep disturbances, and • coping. Each domain was a single question scored on a 0 to 10 continuous NRS. The values for each of these domains were weighed by participant assessment of relative importance and combined in a single value. Total RAID score range was 0 (not affected, very good) to 10 (most affected), where higher value indicated worse status.

Time Frame

Baseline, Weeks 4, 12 and 24

Title

Change From Baseline in Rheumatoid Arthritis Impact of Disease Total Score at Weeks 4 and 12

Description

RAID was a participant reported outcome measure used to evaluate the impact of RA on participant's quality of life which comprised 7 domains: • pain, • function, • fatigue, • physical and psychological wellbeing, • sleep disturbance, and • coping. Each domain was a single question scored on a 0 to 10 continuous NRS. The values for each of these domains were weighed by participant assessment of relative importance and combined in a single value. Total RAID score range was 0 (not affected, very good) to 10 (most affected), where higher value indicated worse status.

Time Frame

Baseline, Weeks 4 and 12

Title

Hospital Anxiety and Depression Scale (HADS): Anxiety (HADS-A) and Depression (HADS-D) Subscale Scores at Baseline, Weeks 4, 12, and 24

Description

Time Frame

Baseline, Weeks 4, 12 and 24

Title

Change From Baseline in Hospital Anxiety and Depression Scale: Anxiety (HADS-A) and Depression (HADS-D) Subscale Scores at Weeks 4, 12 and 24

Description

Time Frame

Baseline, Weeks 4, 12 and 24

Title

Multidimensional Assessment of Thymic States (MAThyS) Scale Total Score at Baseline, Weeks 4, 12 and 24

Description

Time Frame

Baseline, Weeks 4, 12 and 24

Title

Change From Baseline in Multidimensional Assessment of Thymic States Scale Total Score at Weeks 4, 12 and 24

Description

MAThyS was a multi-dimensional self-administered questionnaire comprised of five dimensions (emotional reactivity, cognition speed, psychomotor function, motivation and sensory perception) divided into 20 items relating to individual states as perceived by participants for the preceding week (at each specified Week). Each item was measured on a VAS (in cm) ranging from 0 (inhibition of the state evaluated by the item) to 10 (excitation for the evaluated state). Total MAThyS score was sum of the 20 items and that might vary from score range 0 to 200 with lower scores indicated general inhibition and higher scores indicated general excitation.

Time Frame

Baseline, Weeks 4, 12 and 24

Title

Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Total Scores at Baseline, Weeks 4, 12 and 24

Description

Time Frame

Baseline, Weeks 4, 12 and 24

Title

Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Total Scores at Weeks 4, 12 and 24

Description

Time Frame

Baseline, Weeks 4, 12 and 24

Title

Stanford Health Assessment Questionnaire Disability Index (HAQ-DI) Total Score at Baseline, Weeks 4, 12 and 24

Description

Time Frame

Baseline, Weeks 4, 12 and 24

Title

Change From Baseline in Stanford Health Assessment Questionnaire Disability Index Total Score at Weeks 4, 12 and 24

Description

Time Frame

Baseline, Weeks 4, 12 and 24

Title

Duration of Morning Stiffness at Baseline, Weeks 4, 12, and 24

Description

Time Frame

Baseline, Weeks 4, 12 and 24

Title

Change From Baseline in Duration of Morning Stiffness at Weeks 4, 12, and 24

Description

Time Frame

Baseline, Weeks 4, 12 and 24

Title

International Physical Activity Questionnaire (IPAQ) Total Score at Baseline, Weeks 4, 12 and 24

Description

Time Frame

Baseline, Weeks 4, 12 and 24

Title

Change From Baseline in International Physical Activity Questionnaire Total Score at Weeks 4, 12 and 24

Description

Time Frame

Baseline, Weeks 4, 12 and 24

Title

Patient Global Assessment (PtGA) of Disease Activity Score by Visual Analog Scale (VAS) at Baseline, Weeks 4, 12 and 24

Description

PtGA of disease activity was measured using a 100 millimeters (mm) horizontal VAS ranged from 0=no pain to 100=maximum pain imaginable, where higher score indicated more disease activity.

Time Frame

Baseline, Weeks 4, 12 and 24

Title

Change From Baseline in Patient Global Assessment of Disease Activity Score by Visual Analog Scale at Weeks 4, 12, and 24

Description

PtGA of disease activity was measured using a 100 mm horizontal VAS ranged from 0=no pain to 100=maximum pain imaginable, where higher score indicated more disease activity.

Time Frame

Baseline, Weeks 4, 12 and 24

Title

Erythrocyte Sedimentation Rate (ESR) at Baseline, Weeks 4, 12, and 24

Description

Time Frame

Baseline, Weeks 4, 12 and 24

Title

Change From Baseline in Erythrocyte Sedimentation Rate at Weeks 4, 12, and 24

Description

ESR was a laboratory test to provide non-specific measure of inflammation in the body. The test assessed the rate at which red blood cells fell in a test tube and was measured in mm/h.

Time Frame

Baseline, Weeks 4, 12 and 24

Title

Disease Activity Score-28 for Rheumatoid Arthritis With Erythrocyte Sedimentation Rate (DAS28-ESR) at Baseline, Weeks 4, 12, and 24

Description

Time Frame

Baseline, Weeks 4, 12 and 24

Title

Change From Baseline in Disease Activity Score-28 for Rheumatoid Arthritis With Erythrocyte Sedimentation Rate at Weeks 4, 12, and 24

Description

Time Frame

Baseline, Weeks 4, 12 and 24

Title

Clinical Disease Activity Index (CDAI) Total Score at Baseline, Weeks 4, 12, and 24

Description

Time Frame

Baseline, Weeks 4, 12 and 24

Title

Change From Baseline in Clinical Disease Activity Index Total Score at Weeks 4, 12, and 24

Description

Time Frame

Baseline, Weeks 4, 12 and 24

Title

Number of Swollen Joints at Baseline, Weeks 4, 12, and 24

Description

Number of joints with swelling are reported. Joints which were assessed included 28 joints (which included shoulders, elbows, wrists, knees and 2 joints in each finger and thumb).

Time Frame

Baseline, Weeks 4, 12 and 24

Title

Change From Baseline in Number of Swelling Joints at Weeks 4, 12, and 24

Description

Number of joints with swelling are reported. Joints which were assessed included 28 joints (which included shoulders, elbows, wrists, knees and 2 joints in each finger and thumb).

Time Frame

Baseline, Weeks 4, 12 and 24

Title

Number of Tender Joints at Baseline, Weeks 4, 12, and 24

Description

Number of joints with tenderness are reported. Joints which were assessed included 28 joints (which included shoulders, elbows, wrists, knees and 2 joints in each finger and thumb).

Time Frame

Baseline, Weeks 4, 12 and 24

Title

Change From Baseline in Number of Tender Joints at Weeks 4, 12, and 24

Description

Number of joints with tenderness are reported. Joints which were assessed included 28 joints (which included shoulders, elbows, wrists, knees and 2 joints in each finger and thumb).

Time Frame

Baseline, Weeks 4, 12 and 24

Title

Number of Participants Achieving Low Disease Activity (DAS28 ESR Score <=3.2) and Remission (DAS28 ESR Score <2.6) at Weeks 12, and 24

Description

DAS28-ESR was a composite score that included 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); participant's global assessment of health activity using 100 mm VAS: range 0 (no pain) to 100 (maximum pain imaginable) marker of inflammation assessed by ESR in mm/h. DAS28-ESR total score ranged from 0-10, higher score indicated more disease activity. The DAS28-ESR score provided a number indicating the current disease activity of the RA. A DAS28-ESR score above 5.1 indicated high disease activity, DAS28-ESR score <= 3.2 indicated LDA, > 3.2 to <=5.1 implied moderate disease activity and DAS28-ESR score below 2.6 indicated disease remission.

Time Frame

Weeks 12 and 24

Title

Number of Participants Achieving Clinical Disease Activity Index: Low Disease Activity (CDAI Score <=10.0) and Remission (CDAI Score <=2.8) Weeks 12, and 24

Description

Time Frame

Weeks 12 and 24

Title

Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

Description

Time Frame

Baseline up to end of study (up to 39.7 weeks)

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion criteria : Participants with moderately to severely active RA to European League against Rheumatology (EULAR)/American College of Rheumatology (ACR) Criteria. Participants with moderate to severe disease activity defined as a DAS28-ESR greater than (>) 3.2 at Screening. Participants with inadequate response within at least the last 3 months or intolerance to current csDMARD or to at least one anti-TNF therapy (as defined by the investigator). Oral corticosteroids (less than or equal to [<=] 15 mg/day prednisone or equivalent) and nonsteroidal anti-inflammatory drugs or cyclooxygenase-2 (up to the maximum recommended dose) were allowed if taken at a stable dose for at least 4 weeks prior to Baseline. Permitted csDMARDs were allowed if taken at a stable dose for at least 4 weeks prior to Baseline. Participants abled and given written informed consent and complied with the requirements of the study protocol. Exclusion criteria: Less than (<) 18 years of age. Participant unable to understand and write adequately to complete the study participant related outcome assessments. Exposure to sarilumab at any time prior to Baseline visit. Use of intra-articular or parenteral corticosteroids within 4 weeks prior to Baseline. Treatment with any investigational agent within the 4 weeks of Screening. Last RA treatment prior to inclusion with any anti-Janus kinase (JAK) or biologic DMARD other than anti-TNF. Participants treated with anti-TNF (i.e. adalimumab, infliximab, certolizumab, golimumab, etanercept) before the screening period, which are maintained within the 4 weeks before the inclusion (i.e. the first injection of sarilumab). Rheumatic autoimmune disease other than RA or prior history or current inflammatory joint disease other than RA. Evidence of active malignant disease, malignancies diagnosed within the previous 10 years (except basal and squamous cell carcinoma of the skin or carcinoma in situ of the cervix uteri previously excised and cured). Participant who was institutionalized due to regulatory or legal order or participant who was mentally disabled or educationally disadvantaged. Pregnant or breastfeeding woman. Women of childbearing potential not protected by highly-effective contraceptive method(s) of birth control (as defined in the informed consent form and/or in a local protocol addendum/amendment) over the study period and for at least 3 months following the last dose of sarilumab, and/or who are unwilling or unable to be tested for pregnancy. History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies (or to any of the excipients associated to sarilumab). Immunization with a live/attenuated vaccine within 4 weeks prior to Baseline. Stage III or IV cardiac failure according to the New York Heart Association classification. History of previous gastrointestinal perforation or diverticulitis. Known active current/ recurrent infections (including but not limited to active tuberculosis [TB] or history of incompletely treated TB and atypical mycobacterial disease, hepatitis B and C, and herpes zoster). NOTE: in case of latent TB infection the participant might be included if a subsequent appropriate anti TB treatment is initiated since at least 3 weeks. Positive hepatitis B surface antigen, and/or positive total hepatitis B core antibody, and/or positive hepatitis C antibody at the Screening visit. Evidence of serious uncontrolled concomitant disease, including severe uncontrolled hypercholesterolemia or hypertriglyceridemia. Participants with any of the following laboratory abnormalities at the Screening or Baseline visit: Hemoglobin <8.5 grams per deciliter. White blood cells <3000/cubic millimeter (mm^3). Absolute neutrophil count <2000/mm^3 Absolute lymphocyte count <500/mm^3 Platelet count <150 000 cells/mm^3 Creatinine clearance <30 milliliter per minute. Aspartate aminotransaminase or Alanine aminotransaminase >1.5 x upper limit of normal (ULN). Bilirubin (total) >ULN, unless Gilbert's disease has been determined by genetic testing and has been documented Total fasting cholesterol >3.50 gram per liter (g/L) [9.1 millimoles per liter {mmol/L}]) or triglycerides >5.00 g/L [5.6 mmol/L]). The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Clinical Sciences & Operations

Organizational Affiliation

Sanofi

Official's Role

Study Director

Facility Information:

Facility Name

Investigational Site Number 250007

City

Argenteuil

Country

France

Facility Name

Investigational Site Number 250006

City

Besancon

ZIP/Postal Code

25030

Country

France

Facility Name

Investigational Site Number 250027

City

Bobigny

ZIP/Postal Code

93000

Country

France

Facility Name

Investigational Site Number 250016

City

Bordeaux

ZIP/Postal Code

33076

Country

France

Facility Name

Investigational Site Number 250014

City

Caen

ZIP/Postal Code

14033

Country

France

Facility Name

Investigational Site Number 250032

City

CAHORS Cedex 9

ZIP/Postal Code

46005

Country

France

Facility Name

Investigational Site Number 250019

City

Cannes

ZIP/Postal Code

06414

Country

France

Facility Name

Investigational Site Number 250013

City

Cholet

ZIP/Postal Code

49325

Country

France

Facility Name

Investigational Site Number 250002

City

Clermont Ferrand

ZIP/Postal Code

63003

Country

France

Facility Name

Investigational Site Number 250009

City

Echirolles

ZIP/Postal Code

38434

Country

France

Facility Name

Investigational Site Number 250005

City

La Roche Sur Yon

ZIP/Postal Code

85025

Country

France

Facility Name

Investigational Site Number 250024

City

Le Mans Cedex 9

ZIP/Postal Code

72037

Country

France

Facility Name

Investigational Site Number 250004

City

Lille Cedex

ZIP/Postal Code

59037

Country

France

Facility Name

Investigational Site Number 250012

City

Limoges Cedex

ZIP/Postal Code

87000

Country

France

Facility Name

Investigational Site Number 250021

City

Lyon

ZIP/Postal Code

69495

Country

France

Facility Name

Investigational Site Number 250018

City

Montivilliers

Country

France

Facility Name

Investigational Site Number 250029

City

MONTPELLIER Cedex 5

ZIP/Postal Code

34295

Country

France

Facility Name

Investigational Site Number 250025

City

NANTES Cedex 1

ZIP/Postal Code

44035

Country

France

Facility Name

Investigational Site Number 250026

City

Nice cedex 1

ZIP/Postal Code

06001

Country

France

Facility Name

Investigational Site Number 250020

City

Paris Cedex 10

ZIP/Postal Code

75475

Country

France

Facility Name

Investigational Site Number 250011

City

PARIS Cedex 13

ZIP/Postal Code

75013

Country

France

Facility Name

Investigational Site Number 250010

City

Paris

ZIP/Postal Code

75012

Country

France

Facility Name

Investigational Site Number 250015

City

Paris

ZIP/Postal Code

75014

Country

France

Facility Name

Investigational Site Number 250028

City

Paris

ZIP/Postal Code

75015

Country

France

Facility Name

Investigational Site Number 250033

City

Paris

Country

France

Facility Name

Investigational Site Number 250031

City

Poitiers

ZIP/Postal Code

86021

Country

France

Facility Name

Investigational Site Number 250023

City

Pontoise

ZIP/Postal Code

95300

Country

France

Facility Name

Investigational Site Number 250017

City

RENNES Cedex

ZIP/Postal Code

35022

Country

France

Facility Name

Investigational Site Number 250008

City

Rouen

ZIP/Postal Code

76000

Country

France

Facility Name

Investigational Site Number 250001

City

St Etienne

ZIP/Postal Code

42055

Country

France

Facility Name

Investigational Site Number 250034

City

Strasbourg Cedex 2

ZIP/Postal Code

67098

Country

France

Facility Name

Investigational Site Number 250022

City

Toulouse

ZIP/Postal Code

31200

Country

France

Facility Name

Investigational Site Number 250003

City

Tours

ZIP/Postal Code

37000

Country

France

12. IPD Sharing Statement

Plan to Share IPD

Yes

IPD Sharing Plan Description

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Learn more about this trial

Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis

We'll reach out to this number within 24 hrs

Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis (SariPRO)

Rheumatoid Arthritis

About this trial

Eligibility Criteria

Sites / Locations

Arms of the Study

Arm 1

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

1. Study Identification

2. Study Status

3. Sponsor/Collaborators

4. Oversight

5. Study Description

6. Conditions and Keywords

7. Study Design

8. Arms, Groups, and Interventions

10. Eligibility

12. IPD Sharing Statement

Learn more about this trial